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Low-density lipoprotein cholesterol (LDL-C) is currently the primary target in the management of dys-
lipidemia, and statins are ﬁrst-line pharmacologic interventions. Adjunct therapy such as niacins,
ﬁbrates, bile acid sequestrants, or cholesterol absorption inhibitors may be considered to help reduce
cardiovascular risk. This review discusses the need for alternative adjunct treatment options and the
potential place for omega-3 fatty acids as such. The cardiovascular beneﬁts of ﬁsh consumption are
attributed to the omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), and a
variety of omega-3 fatty acid products are available with varied amounts of EPA and DHA. The product
types include prescription drugs, food supplements, and medical foods sourced from ﬁsh, krill, algal and
plant oils or puriﬁed from these oils. Two prescription omega-3 fatty acids are currently available,
omega-3 fatty acid ethyl esters (contains both EPA and DHA ethyl esters), and icosapent ethyl (IPE;
contains high-purity EPA ethyl ester). A pharmaceutical containing free fatty acid forms of omega-3 is
currently in development. Omega-3 fatty acid formulations containing EPA and DHA have been shown to
increase LDL-C levels while IPE has been shown to lower triglyceride levels without raising LDL-C levels,
alone or in combination with statin therapy. In addition, recent studies have not been able to demon-
strate reduced cardiovascular risk following treatment with ﬁbrates, niacins, cholesterol absorption in-
hibitors, or omega-3 fatty acid formulations containing both EPA and DHA in statin-treated patients;
thus, there remains a need for further cardiovascular outcomes studies for adjunct therapy.
 2013 The Author. Published by Elsevier Ltd. Open access under CC BY-NC-ND license.Contents
1. Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 382
2. Management of dyslipidemia: guidelines and treatment options . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 382
2.1. Fibrates, niacins, bile acid sequestrants, cholesterol absorption inhibitors and the need for other options . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 383
2.2. Omega-3 fatty acids . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 384
2.3. Prescription omega-3 treatment options . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 384
2.3.1. Omega-3 acid ethyl esters (OM3EE) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 385
2.3.2. Icosapent ethyl (IPE) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 385
2.4. Other and emerging omega-3 fatty acid treatment options . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 385
2.4.1. Omega-3 free fatty acids (OM3FFA) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 385
2.4.2. Krill oil . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 386
2.4.3. Algal oil . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 386
2.4.4. Plant oil . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 386
2.5. Omega-3 cardiovascular outcome studies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 386
2.6. Omega-3 considerations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 387
3. Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 387Ltd. Open access under CC BY-NC-ND license.
H. Weintraub / Atherosclerosis 230 (2013) 381e389382Conflict of interest and source of funding . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 388
Acknowledgments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 388
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 388Abbreviations
ACCORD Action to Control Cardiovascular Risk in Diabetes
AHA American Heart Association
AIM-HIGH Atherothrombosis Intervention in Metabolic
Syndrome with Low HDL/High Triglycerides: Impact
on Global Health Outcomes;
ALA alpha linoleic acid;
Apo B apolipoprotein B;
CHD coronary heart disease;
CI conﬁdence interval;
COMBOS Combination of Prescription Omega-3 with
Simvastatin study;
CV cardiovascular;
DHA docosahexaenoic acid;
ECLIPSE Epanova Compared to Lovaza in a Pharmacokinetic
Single-dose Evaluation;
ENHANCE Ezetimibe and Simvastatin in Hypercholesterolemia
Enhances Atherosclerosis Regression trial;
EPA eicosapentaenoic acid;
ESPRIT Efﬁcacy and Safety of Add-on Epanova to Statin in
Subjects With Persistent Hypertriglyceridemia and
High Risk for Cardiovascular Disease study;
EVOLVE Epanova for Lowering Very High Triglycerides study;
FIELD Fenoﬁbrate Intervention and Event Lowering in
Diabetes;
GISSI Gruppo Italiano per lo Studio della Sopravvivenza
nell’Insufﬁcienza cardiaca;
GISSI-HF Gruppo Italiano per lo Studio della Sopravvivenza
nell’Insufﬁcienza cardiaca Heart Failure;
HDL-C high-density lipoprotein cholesterol
HPS2-THRIVE Heart Protection Study 2-Treatment of HDL to
Reduce the Incidence of Vascular Events;
HR hazard ratio;
IPE icosapent ethyl;
IMPROVE-IT Improved Reduction of Outcomes: Vytorin Efﬁcacy
International Trial;
JELIS Japanese EPA Lipid Intervention Study;
LDL-C low-density lipoprotein cholesterol;
Lp-PLA2 lipoprotein-associated phospholipase A2;
MARINE Multi-center, Placebo-controlled, Randomized,
Double-blind, 12-week study with an Open-label
Extension;
NHANES National Health and Nutrition Examination Survey;
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The relationship between low-density lipoprotein cholesterol
(LDL-C) levels and the risk of coronary heart disease (CHD) in a
broad patient population was ﬁrmly established by landmark
studies conducted in the 1980s [1e4]. As a result of widespread
adoption of strategies to lower LDL-C levels over the ensuing three
decades, including the development of statins, mean LDL-C levels
have declined in the United States [5]. Atherogenic dyslipidemia is
characterized by elevated triglycerides (TG) and small LDL particles
with reduced levels of high-density lipoprotein cholesterol (HDL-C)
and often elevated apolipoprotein B (Apo B) and non-HDL-C [6,7].
While LDL-C levels have declined, results from the National Health
and Nutrition Examination Survey (NHANES) showed that 31% of
US adults have high fasting TG levels (150 mg/dL [1.70 mmol/L]),
16% have high TG levels (200 mg/dL; 2.26 mmol/L), and 1% have
very high TG levels (500 mg/dL; 5.65 mmol/L) [8,9]. Substantial
progress has been made in the last decade in understanding the
effects of omega-3 fatty acids on cardiovascular (CV) disease [10]
and lipid parameters including TG and LDL-C [11,12]. The purposeof this review is to provide an update on omega-3 fatty acid
treatment options for patients with dyslipidemia.
2. Management of dyslipidemia: guidelines and treatment
options
LDL-C remains the primary target for lipid-lowering therapy in
the management of dyslipidemia [6,13]. Current recommendations
specify that the LDL-C goal is <100 mg/dL (2.59 mmol/L) for high-
risk patients (CHD or CHD equivalents, including those with dia-
betes; 10-year risk >20%) and <70 mg/dL (1.81 mmol/L) for very-
high-risk patients (multiple major risk factors, severe and poorly
controlled risk factors, multiple risk factors of the metabolic syn-
drome and acute coronary syndrome) [13]. Non-HDL-C is the sec-
ondary target in patients with TG  200 mg/dL (5.18 mmol/L) [6].
Therapeutic lifestyle changes are an essential ﬁrst-line modality for
clinical management of dyslipidemia in all patients [6,13]. For in-
dividuals who cannot attain target LDL-C levels with diet and ex-
ercise alone, statins are ﬁrst-line pharmacotherapy [6]. In patients
with dyslipidemia and elevated LDL-C, ﬁbrates and niacins can be
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is the secondary target in patients with TG  200 mg/dL
(2.26 mmol/L) and TG-lowering agents such as ﬁbrates or niacins
can be considered in addition to statins [6]. In patients with dys-
lipidemia and low LDL-C, ﬁbrates can be used as monotherapy if
CHD is present and niacins can be used as monotherapy if higher
risk is present [6]. The use of bile acid sequestrants is recommended
in speciﬁc populations including patients who require modest re-
ductions in LDL-C to achieve target goals or have moderate eleva-
tions in LDL-C, young persons with elevated LDL-C, women with
elevated LDL-C who are considering pregnancy, and in patients
with very high LDL-C who require combination therapy with sta-
tins [6]. Cholesterol absorption inhibitors may be used to reduce
elevated total cholesterol (TC), LDL-C, Apo B, and non-HDL-C in
patients with primary hyperlipidemia (alone or in combination
with statins) or in patients with mixed hyperlipidemia (alone or in
combinationwith fenoﬁbrate) [14]. To reduce CV risk, the American
Heart Association (AHA) recommends consumption of two servings
of fatty ﬁsh per week for all adults [15]; dietary consumption of ﬁsh
has long been associated with reduced CV risk/outcomes and TG
lowering [16e18]. The beneﬁcial effects of ﬁsh consumption are
attributed to the omega-3 fatty acids eicosapentaenoic acid (EPA;
C20:5n-3) and docosahexaenoic acid (DHA; C22:6n-3) [15]; thus,
the AHA also recommends that individuals with CHD consume a
combined 1000 mg/day of EPA and DHA [15].
2.1. Fibrates, niacins, bile acid sequestrants, cholesterol absorption
inhibitors and the need for other options
Trials assessing the efﬁcacy of ﬁbrates in lowering CV risk have
yielded mixed results. CV risk was signiﬁcantly lower in patients
receiving gemﬁbrozil versus those receiving placebo in the Veter-
ans Affairs High-density Lipoprotein Intervention Trial (VA-HIT;
N ¼ 2531) [19]. The same results were seen in a subpopulation of
patients from the VA-HIT trial with diabetes [20]. However, in the
Fenoﬁbrate Intervention and Event Lowering in Diabetes (FIELD)
trial (N ¼ 9795) [21] involving patients with diabetes, fenoﬁbrate
monotherapy did not signiﬁcantly reduce the likelihood of reaching
the composite end point of CHD death or nonfatal myocardial
infarction, although the lack of efﬁcacy could be attributed to statin
use in the placebo group [21]. In the Action to Control Cardiovas-
cular Risk in Diabetes (ACCORD) trial (N ¼ 5518) [22] involving
high-risk patients with type 2 diabetesmellitus (T2DM), addition of
ﬂexible-dose fenoﬁbrate or placebo to simvastatin therapy resulted
in statistically similar annual rates of nonfatal myocardial infarc-
tion, nonfatal stroke, or CV death (hazard ratio [HR], 0.92; 95%
conﬁdence interval [CI]: 0.79e1.08; p ¼ 0.32). Median TG levels
decreased from 1.85 mmol/L at baseline to 1.38 mmol/L in the
fenoﬁbrate group and from 1.81 mmol/L at baseline to 1.63 mmol/L
in the placebo group over an average follow-up of 4.7 years, and
more patients in the fenoﬁbrate group had either a dose reduction
or discontinuation due to reduction in glomerular ﬁltration rates
[22]. As has been observed in other fenoﬁbrate trials, small in-
creases in mean serum creatinine levels (from 91 to 92 mmol/L)
occurred during the ﬁrst year of fenoﬁbrate therapy. Notwith-
standing mixed results from the aforementioned individual trials, a
meta-analysis of studies involving patients with atherogenic dys-
lipidemia (TG > 200 mg/dL [2.26 mmol/L] and/or HDL-C < 40 mg/
dL [1.04 mmol/L]) suggested addition of fenoﬁbrate to statin ther-
apy may be beneﬁcial [23]. In patients with both hyper-
triglyceridemia and reduced HDL-C (N ¼ 5068), the relative risk
ratio for occurrence of vascular events compared with placebo was
0.71 (95% CI: 0.62e0.82, p < 0.001).
Similar results were found with the addition of niacin to
simvastatin. The Atherothrombosis Intervention in MetabolicSyndrome with Low HDL/High Triglycerides: Impact on Global
Health Outcomes (AIM-HIGH) study (N ¼ 3414) [24] was stopped
early because of lack of efﬁcacy of niacin (1500e2000 mg/day)
added to simvastatin therapy in patients with established CV dis-
ease and low LDL-C levels (<1.81 mmol/L). Despite improvement in
HDL-C (15% greater increase with niacin vs placebo, p < 0.001) and
TG levels (21% greater decrease with niacin vs placebo), the HR for
the primary CV outcome was 1.02 (95% CI: 0.87e1.21, p ¼ 0.80) for
simvastatin plus niacin vs simvastatin alone. Moreover, in the
combination treatment group, signiﬁcantly more patients dis-
continued the study drug than in the simvastatin-only group (25.4%
vs. 20.1%, p< 0.001). Flushing or itching resulted in discontinuation
in 6.1% in the combination treatment group. Flushing, a common
side effect of niacin, is reported by 75% of patients [25]. More
recently, the Heart Protection Study 2-Treatment of HDL to Reduce
the Incidence of Vascular Events (HPS2-THRIVE) study reported
reductions in TG and LDL-C levels of 0.37 mmol/L and 0.26 mmol/L,
respectively, with an increase in HDL-C of 0.16 mmol/L following
treatment with extended-release niacin/laropiprant; baseline
lipids while on statin-based therapy in this group were: TC,
3.32 mmol/L; LDL-C, 1.63 mmol/L; HDL-C, 1.14 mmol/L; and TG,
1.43 mmol/L [26]. However, preliminary outcomes results indicated
that the combination of extended-release niacin/laropiprant with
statin therapy did not signiﬁcantly further reduce the risk of major
vascular events compared with statin therapy alone (risk
ratio ¼ 0.96 [95% CI 0.90e1.03]; p ¼ 0.29).
Trials assessing the effects of adding a bile acid sequestrant to a
statin regimen have demonstrated improvements in patient lipid
proﬁles. Total cholesterol and LDL-C were signiﬁcantly lower with
the combination of colesevelam 3.8 g plus simvastatin 10 mg or
colesevelam 2.3 g plus simvastatin 20 mg versus placebo compared
with any of the individual agents alone [27]. Despite the im-
provements in lipid proﬁles, use of bile acid sequestrants is limited
by an inconvenient mode of administration and frequency of
gastrointestinal adverse effects, with constipation reported in 10%
and 28% of patients who receive colestipol and cholestyramine,
respectively [28]. Additionally, bile acid sequestrants can increase
TG levels, and use is contraindicated in patients with TG levels
500 mg/dL (5.65 mmol/L) [29].
While the lipid-lowering efﬁcacy and safety of the cholesterol
absorption inhibitor ezetimibe were established through a range of
clinical studies including investigations of combination use with
statins [14], controversy emerged with regard to ezetimibe’s
vascular and clinical beneﬁt due to the disappointing results of the
Ezetimibe and Simvastatin in Hypercholesterolemia Enhances
Atherosclerosis Regression (ENHANCE) trial [30]. In this double-
blind, 24-month trial, 720 patients with familial hypercholester-
olemia received 80 mg of simvastatin with placebo or 10 mg of
ezetimibe and were assessed for intima-media thickness of the
walls of the carotid and femoral arteries (primary end point; a
commonly used risk surrogate for vascular disease). The study re-
sults indicated that while combined therapy with ezetimibe and
simvastatin reduced LDL-C, it did not result in signiﬁcant differ-
ences in the primary end point. A currently ongoing trial, Improved
Reduction of Outcomes: Vytorin Efﬁcacy International Trial
(IMPROVE-IT), is an event-driven study with a minimum of 5250
subjects experiencing a primary end point event and seeking to
compare the effect of ezetimibe and simvastatin to simvastatin
monotherapy on death due to cardiovascular events, nonfatal cor-
onary events, and nonfatal strokes [31].
The mixed and disappointing results of clinical studies investi-
gating CV outcomes and/or the associated adverse events of
ﬁbrates, niacins, bile acid sequestrants, or cholesterol absorption
inhibitors highlight the need for alternative treatment options such
as omega-3 fatty acids.
Table 1
Omega-3 fatty acid products.
Product Brand name Active ingredient(s) Dose Clinical studies/reviews
Approved prescription drugs
Omega-3-acid ethyl
esters
Lovaza Ethyl esters of omega-3
fatty acids sourced from
ﬁsh oils [37]
Each 1-g capsule contains at least
900 mg of ethyl esters of omega-3 fatty
acids: EPA ethyl ester (w465 mg) and
DHA ethyl ester (w375 mg) taken as 4
capsules once daily or 2 capsules twice
daily [37]
Harris et al. [39]
Pownall et al. [40]
Davidson et al. (COMBOS) [41]
Icosapent ethyl Vascepa IPE, the ethyl ester of
the omega-3 fatty acid
EPA [75]
Each capsule contains 1 g of IPE; daily
oral dose of 4 g taken as 2 capsules
twice daily [75]
Bays et al. (MARINE) [45]
Ballantyne et al. (ANCHOR) [46]
Emerging prescription agents and dietary supplements
Free fatty acids Epanova Free fatty acid forms of
EPA and DHA
Each 1-g capsule contains 75% EPA and
DHA free fatty acids; studies have
included
2 g/day to 4 g/day doses [47]
Davidson et al. (ECLIPSE) [48]
EVOLVE: NCT01242527 [49]
ESPRIT: NCT01408303 [51]
Reviewed by Katoaka et al., 2013 [76]
Fish oil supplements Various EPA and DHA; other
components
Purity and amount of EPA and DHA
varies; median (25e75 percentile)
amount per serving: EPA, 216 (160
e360) mg; DHA, 200 (120e240) mg
taken as 1e3 soft gels, capsules, or
packets per serving; liquid forms also
available [77]
Reviewed by Zargar 2011 [77] and
Tur et al., 2012 [58]
Krill oil supplements Neptune Krill
Oil (NKO),
Superba,
CaPre
EPA and DHA; other
components
30% EPA and DHA, 40% phospholipids
(primarily phosphatidyl choline) and
astaxanthin, vitamin A, vitamin E, and
other fatty acids [78]; studied doses
have included 1 g/day to 3 g/day [53]
Bunea et al. [53]
NCT01415388 [55]
TRIFECTA: NCT01455844 [54]
Algal oil supplements Various DHA; other fatty acids;
other components;
some may also contain
EPA
Purity and amount of DHA varies; EPA
may also be present [56]; median DHA
dose in meta-analysis of 11 RCTs:
1.68 g/day [57]
Reviewed by Bernstein et al., 2012 [57]
and Tur et al., 2012 [58]
Plant oil supplements Various ALA; other components Purity and amount of ALA varies and
can be sourced from ﬂaxseed and other
plant sources [58]
Reviewed by Pan et al., 2012 [59] and
Tur et al., 2012 [58]
ALA ¼ alpha-linolenic acid; COMBOS ¼ Combination of Prescription Omega-3 with Simvastatin study; DHA ¼ docosahexaenoic acid; EPA ¼ eicosapentaenoic acid;
ESPRIT¼ Efﬁcacy and Safety of Add-on Epanova to Statin in Subjects With Persistent Hypertriglyceridemia and High Risk for Cardiovascular Disease study; EVOLVE¼ Epanova
for Lowering Very High Triglycerides study; IPE¼ icosapent ethyl; MARINE¼Multi-center, Placebo-controlled, Randomized, Double-blind, 12-Week Studywith an Open-label
Extension; RCT ¼ randomized controlled trial; TRIFECTA ¼ Trial for Efﬁcacy of CaPre on Hypertriglyceridemia.
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The potential CV beneﬁts of EPA and DHA have been well
recognized, and both have potent TG-lowering effects [15]. While
the TG-lowering effects of DHA and EPA have been established,
evidence is accumulating as to the differential effects of these two
omega-3 fatty acids on other lipoprotein parameters, particularly
LDL-C. Results of several small trials in varied populations of pa-
tients with mild to moderate TG elevations have suggested that EPA
does not raise LDL-C [32e35]. Recently, these observations have
been supported by two separate meta-analyses using data from 21
and 22 randomized controlled trials, respectively [11,12]. Wei et al.
[11] found that while both EPA and DHA lowered TG, DHA raised
LDL-C but EPA did not. Jacobson et al. [12] also found that DHA
treatment was associated with LDL-C increases and noted that EPA
treatment was associated with reductions or smaller increases in
LDL-C. In addition to differential effects on LDL-C, both analyses
found that DHA was associated with increases in HDL-C while EPA
was not. Jacobson et al. also found that EPA was associated with
greater average reductions in non-HDL-C than was DHA. Since the
publication of these meta-analyses, a randomized, double-blind,
double-dummy, head-to-head study in Japan reported the lipid-
lowering effects of 2 g/day or 4 g/day of EPA ethyl ester plus DHA
ethyl ester (0.465 g EPA ethyl ester plus 0.375 g DHA ethyl ester per
1-g capsule) versus 1.8 g/day of pure EPA ethyl ester alone [36].
In 611 patients with hypertriglyceridemia (TG  150 mg/dL[1.70 mmol/L] and <750 mg/dL [8.48 mmol/L]), all 3 treatments
produced substantial decreases in TG levels, small increases in HDL-
C levels and small decreases in LDL-C levels comparedwith baseline.
However, EPA ethyl ester produced numerically greater reductions
in LDL-C levels than either dose of EPA ethyl ester plus DHA ethyl
ester. While noting that the study was limited to Japanese patients
undergoing lifestyle modiﬁcation, the authors also pointed out that
increased LDL-C levels have been observed in other studies of
omega-3 fatty acids. Roughly 43% of these patients were taking a
statin at baseline; LDL-C changes in the nonstatin subgroups were
not published. Together, the available evidence suggests that EPA
monotherapy may have clinical beneﬁt, as such therapy may not
interfere with reaching or maintaining target LDL-C levels.
Omega-3 fatty acids are available in the form of prescription
drugs, dietary supplements from ﬁsh oil, krill oil, algal oil, and plant
oil as well as emerging options such as free fatty acids (Table 1).
2.3. Prescription omega-3 treatment options
Until recently, the only United States Food and Drug Adminis-
tration (US FDA)-approved prescription marine omega-3 fatty acid
formulation was Lovaza (omega-3 acid ethyl esters [OM3EE];
GlaxoSmithKline, Research Triangle Park, NC; marketed outside the
US as Omacor [Europe], Zodin [Germany], or Lotriga [Japan])
[37]. Each 1-g capsule of Lovaza contains 465 mg of EPA ethyl ester
and 375 mg of DHA ethyl ester derived from ﬁsh oil [37]. OM3EE is
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with TG levels 500 mg/dL (5.65 mmol/L). Icosapent ethyl (IPE;
Vascepa [formerly AMR101]; Amarin Pharma Inc., Bedminster, NJ)
is a high-purity prescription form of EPA ethyl ester that was
approved by the US FDA in 2012 as an adjunct to diet to reduce TG
levels in adult patients with severe (500 mg/dL [5.65 mmol/L])
hypertriglyceridemia. A prescription ethyl EPA formulation is also
available in Japan as Epadel [38].
2.3.1. Omega-3 acid ethyl esters (OM3EE)
The pivotal double-blind, placebo-controlled trials by Harris
et al. and Pownall et al. [39,40] were designed to assess the effects
of OM3EE on lipid proﬁles in patients with very high TG levels
(5.65 mmol/L and 22.6 mmol/L). Although not speciﬁed in the
study design, patients did not take statins during the trials. In both
trials, TG levels decreased substantially at the ﬁrst study visit after
initiation of active treatment (1 month in the Harris study and 2
weeks in the Pownall study). At the end of both studies, signiﬁcant
reductions were observed in TG and total cholesterol (TC) levels,
and signiﬁcant increases were observed in HDL-C levels. However,
notable increases from baseline were observed in LDL-C following
OM3EE treatment that were statistically signiﬁcant compared with
placebo (Harris: 32%, p ¼ 0.0014; Pownall: 16.7%, p ¼ 0.013).
In the Combination of Prescription Omega-3 with Simvastatin
(COMBOS) study, Davidson et al. assessed the TG-lowering
efﬁcacy and safety of OM3EE in patients with persistent hyper-
triglyceridemia despite receiving statin therapy [41]. The 8-week
study randomized 256 patients with fasting TG  200 (2.26 mmol/
L) and <500 mg/dL (5.65 mmol/L) and mean LDL-C levels 10% of
their National Cholesterol Education ProgrameAdult Treatment
Panel III goal [41]. Patients received simvastatin 40 mg with 4 g/day
OM3EE or placebo, and the primary outcome was the mean change
from baseline in non-HDL-C levels at study end. Themedian percent
reduction in TG levels was signiﬁcantly different between the
treatment groups (29.5%, OM3EE plus simvastatin; 6.3%, simvastatin
alone; p< 0.001). Changes in LDL-Cwere observed, but therewas no
signiﬁcant difference between groups (þ0.7%, OM3EE plus
simvastatin;2.8%, simvastatin alone; p¼0.052). Percent reductions
were signiﬁcantly different for OM3EE plus simvastatin vs. simva-
statin alone for non-HDL-C (9.0% vs. 2.2%; p < 0.001), very-low-
density lipoprotein cholesterol (VLDL-C; 27.5% vs. 7.2%; p < 0.001)
and Apo B (4.2% vs. 1.9%; p¼ 0.023). OM3EE has also been studied in
patients receiving atorvastatin [42]. Signiﬁcant reductions were
noted for TG, non-HDL-C, and VLDL-C levels, while changes in LDL-C
and Apo B levels were not statistically signiﬁcant [42].
OM3EE was generally well tolerated in clinical trials; adverse
events reported by 3% of patients that occurred more frequently
than in patients receiving placebo were eructation, dyspepsia, and
taste perversion [37]. In the pivotal study reporting safety data,
treatment did not affect liver function [39]. This may be clinically
relevant, as ﬁbrates and niacins are associated with hepatic trans-
aminase elevations [43,44]. Adverse-event rates in the combination
therapy trial were similar in the OM3EE plus simvastatin and
simvastatin-alone groups, as were study completion rates (94.3%,
OM3EE plus simvastatin; 95.5%, simvastatin alone) [41]. While the
safety and TG-lowering efﬁcacy of OM3EE have clearly been
established, the increases in LDL-C levels could present difﬁculties
for achievement of LDL-C treatment goals.
2.3.2. Icosapent ethyl (IPE)
The pivotal Multi-center, Placebo-controlled, Randomized,
Double-blind, 12-Week Study with an Open-label Extension
(MARINE)was a large, international trial involving patientswith very
high TG levels (500 [5.65 mmol/L] and 2000 mg/dL [22.6 mmol/
L]) [45]. This three-arm study randomized 229 patients to IPE 4 g/day, IPE 2 g/day, or placebo. The primary efﬁcacy outcome was the
median placebo-adjusted percent change in TG levels from baseline
to week 12. Although changes were typically greater in the 4 g/day
group, both doses of IPE improved lipid proﬁles compared with
placebo: TG levels were signiﬁcantly reduced by 33.1% (p < 0.0001)
and 19.7% (p ¼ 0.0051) with IPE 4 g/day and 2 g/day, respectively.
Importantly, LDL-C levels were not signiﬁcantly increased. Re-
ductions were also observed for non-HDL-C, VLDL-C, lipoprotein-
associated phospholipase A2 (Lp-PLA2), Apo B, TC, and very-low-
density lipoprotein triglycerides (VLDL-TG) levels, and all were sig-
niﬁcant in the IPE 4 g/day group (17.7%, 28.6%,13.6%, 8.5%,16.3%, and
25.8%, respectively; all p < 0.01); no signiﬁcant changes were
observed for HDL-C levels.
The 12-week ANCHOR study [46] evaluated the efﬁcacy and
safety of IPE in patients with persistent high TG levels (200
[2.26mmol/L] and<500mg/dL [5.65mmol/L]) despite havingwell-
controlled LDL-C levels while on optimized statin therapy, with
w73% diagnosed with diabetes mellitus. Patients (N ¼ 702) were
randomized to receive IPE 4 g/day, 2 g/day, or placebo, and the
primary outcome measure, as in the MARINE study, was median
placebo-adjusted percent change inTG levels frombaseline to study
end. TG levels were signiﬁcantly reduced by 21.5% (p < 0.0001) and
10.1% (p ¼ 0.0005) with IPE 4 g/day and 2 g/day, respectively. As
seen in the MARINE study, favorable results were also observed in
terms of LDL-C levels compared with placebo. In the ANCHOR
population with well-controlled LDL-C levels at baseline, LDL-C
levels were not signiﬁcantly increased with IPE 2 g/day and were
signiﬁcantly decreased with IPE 4 g/day (6.2%; p ¼ 0.0067). Signif-
icant reductions (all p < 0.0001) were also observed for non-HDL-C
(13.6%), VLDL-C (24.4%), Lp-PLA2 (19.0%), Apo B (9.3%), TC (12.0%),
and VLDL-TG (26.5%) levels compared with placebo for IPE 4 g/day.
IPE was generally well tolerated in both 12-week studies. Most
adverse events in the MARINE and ANCHOR studies were consid-
ered unrelated to treatment, with adverse-event rates low and
similar between IPE groups and placebo [45,46]. IPE treatment did
not affect kidney or liver function evaluations, blood glucose, or
HbA1c levels, even when given in combination with statins. As
mentioned earlier, this may offer clinical beneﬁt over ﬁbrates and
niacins. While ﬁshy eructations are often reported for other omega-
3 fatty acid products, fewer patients receiving IPE reported eruc-
tations than patients in the placebo groups. Compliance was high,
withmore than 90% of patients completing treatment in both trials.
2.4. Other and emerging omega-3 fatty acid treatment options
2.4.1. Omega-3 free fatty acids (OM3FFA)
OM3FFA (Epanova; Omthera Pharmaceuticals, Princeton, NJ,
USA), is a puriﬁed mixture of the free fatty acid forms EPA and DHA
with amounts of EPA and DHA that are comparable to OM3EE [47].
In the Epanova Compared to Lovaza in a Pharmacokinetic Single-
dose Evaluation (ECLIPSE), the bioavailability of OM3FFA was
found to be 4-fold greater than that of OM3EE during low-fat con-
sumption periods [48]. The Epanova for Lowering Very High Tri-
glycerides (EVOLVE) studywas conducted to ascertain the efﬁcacy of
OM3FFA compared with placebo in lowering TG in patients with
severe hypertriglyceridemia [49,50]. The 12-week study random-
ized 399 subjects with TG levels 500 mg/dL (5.65 mmol/L) to
2000mg/dL (22.6mmol/L). Patients received 2 g/day, 3 g/day, or 4 g/
day of OM3FFA or 4 g/day of olive oil and the primary outcome was
percent change in TG level from baseline to week 12. There were
signiﬁcant reductions in median percent change from baseline in TG
levels of 25.8% (p ¼ 0.003), 21.7% (p ¼ 0.021), and 30.7% (p < 0.001)
and median percent increases from baseline in LDL-C of 21.4%
(p ¼ 0.003), 15.5% (p ¼ 0.092), and 26.2% (p < 0.001) in the 2 g/day,
3 g/day, and 4 g/day groups, respectively. Signiﬁcant reductions
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(34.7%; p < 0.001) with nonsigniﬁcant increases in HDL-C and Apo
B in the 4 g/day group. OM3FFA was also found to be safe and well
tolerated. Discontinuations due to adverse events (5e7% in the
active treatment arms) were primarily gastrointestinal in nature.
OM3FFA has also been investigated in statin-treated patients in
the recently completed ESPRIT trial (Efﬁcacy and Safety of Add-on
Epanova to Statin in Subjects With Persistent Hyper-
triglyceridemia and High Risk for Cardiovascular Disease) [51,52].
This 6-week, double-blind study randomized 647 diet-stable pa-
tients with TG levels 200 mg/dL (2.26 mmol/L) and <500 mg/dL
(5.65 mmol/L) who were on a maximally tolerated dose of statin or
statin/ezetimibe therapy with persistently high TG levels and high
risk for cardiovascular disease to olive oil, 2 g/day OM3FFA, or 4 g/
day OM3FFA. The primary end point was mean percent change in
non-HDL-C from baseline to end of treatment. Non-HDL-C was
reduced in both the 2 g/day (3.9%; p ¼ 0.0373) and 4 g/day (6.9%;
p < 0.0001) treatment groups. Mean reductions in TG of 14.6%
(p< 0.0001) and 20.6% (p< 0.0001), as well as increases in LDL-C of
4.6% (p ¼ 0.0247) and 1.3% (p ¼ 0.6470) were also reported for the
2 g/day and 4 g/day groups, respectively. Signiﬁcant reductions
were observed for VLDL-C (21.5%; p < 0.0001), Apo B (2.1%;
p ¼ 0.0352), and Lp-PLA2 (10.7%; p < 0.0001), with a nonsigniﬁcant
increase of 3.3% in HDL-C in the 4 g/day group.
2.4.2. Krill oil
Krill oil, as provided by Antarctic krill, is a rich source of phos-
pholipids containing long-chain omega-3 polyunsaturated fatty
acids (PUFAs; primarily EPA and DHA) along with antioxidants such
as vitamins A and E and astaxanthin [53]. A double-blind, random-
ized trial assessed the effect of krill oil (Neptune Krill Oil [NKO];
Neptune Technologies & Bioresources, Laval, Quebec, Canada), onTC,
TG, LDL-C, and HDL-C [53]. The 12-week study randomized 120
patientswith at least a 6-month diagnosis ofmildly high to very high
cholesterol (193.9 mg/dL [5.02 mmol/L] 347.9 mg/dL [8.93 mmol/
L]) and TG (203.8 mg/dL [2.30 mmol/L] 354.4 mg/dL [4.00 mmol/
L]). Patients received krill oil (1, 1.5, 2, or 3 g/day) as determined by
body mass index, ﬁsh oil (3 g once daily: 180 mg EPA and 120 mg
DHA per gram), or placebo (3 g once daily). Signiﬁcant changes were
observed in TC, LDL-C, and HDL-C in all the krill oil groups
(18.1%, 37.4%, þ55.3% in the 2 g/day group and 17.9%, 39.2%,
andþ59.6% in the 3 g/daygroup, respectively); signiﬁcant reductions
inTGwere observed in the 2 g/day group (27.6%) and 3 g/day (26.5%),
but not in lower-dose groups [53]. Currently, the 12-week TRIFECTA
study (Trial for Efﬁcacy of CaPre on Hypertriglyceridemia) [54] is
assessing whether 1 g/day or 2 g/day of a krill oil product (CaPre;
Acasti Pharma, Laval, Quebec, Canada) has aneffect on fasting plasma
TG in patients with mild to high hypertriglyceridemia compared
with placebo (stable statin dose is permitted). In addition, a 12-week
study [55] investigating the effects of Superba krill oil (Aker Bio-
Marine ASA, Oslo, Norway) on change frombaseline in fasting serum
TG and the omega-3 index was recently completed.
2.4.3. Algal oil
Algal oil is another potential resource for omega-3 fatty acids
[56]. The clinical literature describing the relationship between algal
oil use and CV risk factors comprises a few small studies. As such, a
meta-analysis conducted by Bernstein et al. examined the impact of
algal oil supplementation on TG, HDL-C, and LDL-C. This analysis of
randomized controlled trials dating from 1996 to 2011 included a
total of 485 patients [57]. The mean age of patients across the
included trials ranged from 24 to 59 years. The studies were mostly
6 weeks in duration. TG decreased with algal oil supplementation,
whereas LDL-C and HDL-C increased (TG, e15% [95% CI: 10e20%];
LDL-C, þ8% [95% CI: 6e10%]; HDL-C, þ5% [95% CI: 4e7%]) [57].2.4.4. Plant oil
Plant oil from food sources such as ﬂaxseed and walnuts is a
resource for the omega-3 fatty acid alpha-linoleic acid (ALA) [58].
The relationship between ALA exposure and risk of CV disease was
examined in a systematic review and meta-analysis by Pan et al.
[59]. This analysis included 27 studies with 251,049 patients and
15,327 CV disease events. Taking into consideration both dietary
intake of ALA and biomarker concentration, the overall relative risk
of CV disease event was 0.86 (95% CI: 0.77e0.97). Recently, a meta-
analysis of omega-6 linoleic acid studies by Ramsden et al. was
updated by incorporating recovered data from the Sydney Diet
Heart Study [60]. Analysis of the recovered data from 458men aged
30e59 years demonstrated higher rates of CV mortality (HR: 1.7
[95% CI: 1.03e2.80]; p ¼ 0.037) and mortality from CHD (HR: 1.74
[95% CI: 1.04e2.92]; p ¼ 0.036) in the intervention group (wherein
dietary saturated fats from animal fats and common margarines
and shortenings were replaced with omega-6 linoleic acid from
safﬂower and sunﬂower oils) compared with the control group.
Incorporating these results into the meta-analysis resulted in no
evidence of CV beneﬁt for omega-6 linoleic acid.
2.5. Omega-3 cardiovascular outcome studies
The Japanese EPA Lipid Intervention Study (JELIS) investigated
the effects of puriﬁed EPA for prevention of major coronary events
[61]. A total of 18,645 Japanese individuals with hypercholester-
olemia (TC 6.5mmol/L) were randomized to receive 1800mg/day
EPA plus a statin (pravastatin or simvastatin) or statin only over 5
years. In 2007, the JELIS study reported that the risk of major cor-
onary events was reduced by 19% in the EPA group compared with
the statin-only group (p ¼ 0.011). Moreover, a subgroup analysis of
patients from the JELIS study demonstrated that those with
TG  150 mg/dL (1.70 mmol/L) and HDL-C <40 mg/dL (1.04 mmol/
L) had a signiﬁcantly higher risk of major coronary events (com-
bined HR: 1.71 [95% CI: 1.11e2.64]; p ¼ 0.014) at the time of study
registration compared with patients with TG < 150 mg/dL
(1.70 mmol/L) and HDL-C 40 mg/dL (1.04 mmol/L) [62]. However,
EPA treatment lowered the risk of major coronary events by 53% in
the group with TG  150 mg/dL (1.70 mmol/L) and HDL-C <40 mg/
dL (1.04 mmol/L) (HR: 0.47 [95% CI: 0.23e0.98]; p¼ 0.043). In 1999,
the Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto
Miocardico (GISSI)-Prevenzione study of 11,324 patients with
recent myocardial infarction demonstrated a signiﬁcant relative
decrease of 10% (p¼ 0.048) in the risk of the combined end point of
death, nonfatal myocardial infarction, and nonfatal stroke in pa-
tients treated with 850e882 mg/day of combined EPA and DHA
ethyl esters [63]. The later Gruppo Italiano per lo Studio della
Sopravvivenza nell’Insufﬁcienza cardiaca Heart Failure (GISSI-HF)
study (N ¼ 7046) demonstrated a risk reduction of 1.8% (95% CI:
0.3e3.9) for all-cause mortality in patients with clinical evidence of
heart failure who had been treated with omega-3 fatty acids [64].
While these earlier studies of CV outcomes reported favorable
effects of omega-3 fatty acids, recent CV outcomes studies of EPA
and DHA combination therapy have been disappointing. In the
randomized, double-blind, placebo-controlled Alpha Omega
trial (N ¼ 4837), the CV beneﬁts of omega-3 fatty acid supple-
mentation were evaluated [65]. Patients with previous myocardial
infarction who were receiving state-of-the-art antihypertensive,
antithrombotic, and lipid-modifying therapy were assigned to use
margarine containing a combination of EPA plus DHA; the plant-
based omega-3 fatty acid ALA; a combination of EPA, DHA, and
ALA; or placebo for 40 months. Active treatment groups had an
average additional daily intake of 226 mg EPA combined with
150 mg DHA, 1.9 g ALA, or both. At the end of the study, there were
no statistically signiﬁcant differences in the incidence of the
H. Weintraub / Atherosclerosis 230 (2013) 381e389 387combination of fatal or nonfatal CV events across treatment groups
(HR, EPA plus DHA: 1.01 [95% CI: 0.87e1.17]; p¼ 0.93; HR, ALA: 0.91
[95% CI: 0.78e1.05]; p¼ 0.20) [65]. In this trial, the beneﬁcial effects
of low-dose EPA plus DHA therapy may have been difﬁcult to prove
because the patients were receiving state-of-the-art clinical care.
In the randomized, placebo-controlled Omega 3 Fatty Acids on
Top of Modern Guideline-adjusted Therapy (OMEGA) trial, patients
with acute myocardial infarction (N ¼ 3851) received 1-g capsules
containing either 460 mg EPA and 380 mg DHA or placebo daily in
addition to guideline-adjusted therapy and were followed for 1
year [66]. Rates for the primary efﬁcacy outcome of sudden cardiac
death were 1.5% in both study arms (p ¼ 0.84) Differences in sec-
ondary end points such as major CV or cerebrovascular events were
also statistically similar. Interpretation of the results from the
OMEGA trial was limited because the study lacked sufﬁcient sta-
tistical power. The sample size and event rates used in the OMEGA
study were based on prior studies, but the patient population was
receiving considerably improved guideline-adjusted treatment of
acute myocardial infarction, and thus the number of sudden death
events was lower than expected. The Alpha Omega and OMEGA
trials may have both been limited by insufﬁcient duration; the
relatively low dose of omega-3 fatty acids may also have been a
limiting factor in the Alpha Omega trial.
The effects of long-term treatment with 1-g capsules containing
465 mg EPA and 375 mg DHA on CV events was examined in the
Outcome Reduction with Initial Glargine Intervention (ORIGIN)
trial in patients with T2DM, impaired fasting glucose, or impaired
glucose tolerance (N¼ 12,536) [67]. The study found that 1 g/day of
EPA/DHA did not prevent death or any CV outcomes in this patient
population. As with the Alpha Omega trial, the ORIGIN trial may
have been limited by concomitant cardioprotective therapies which
may have reduced the statistical power to detect any effect of
omega-3 fatty acid intervention. Other limitations may have
included relatively low-dose supplementation and low dietary
intake of omega-3 fatty acids. It may be worth noting that in the
JELIS study, where cardiovascular outcomes were improved in pa-
tients who received both statins and EPA as comparedwith patients
who received statins alone, the omega-3 therapy contained EPA
without DHA and the dose was nearly 2 g/day.
In the Omega-3 Fatty Acids for Prevention of Post-operative
Atrial Fibrillation (OPERA) trial, the effects of perioperative
omega-3 PUFA supplementation on the occurrence of post-
operative atrial ﬁbrillation was assessed in patients who under-
went cardiac surgery (N ¼ 1516) [68]. No signiﬁcant difference was
observed between patients who received the perioperative omega-
3 PUFA supplementation and thosewho received placebo (omega-3
PUFA, 30.0% vs. placebo, 30.7%; p ¼ 0.74; odds ratio: 0.96 [95% CI:
0.77e1.20]). Of note, stroke incidence (secondary end point)
occurred less frequently in patients treated with omega-3 PUFA
supplementation (omega-3 PUFA, 0.5% vs. placebo, 1.1%; odds ratio:
0.45 [95% CI: 0.13e1.51]), although the difference was not statisti-
cally signiﬁcant (p ¼ 0.18). In response, a meta-analysis conducted
by Larsson et al. assessed the relationship between omega-3 PUFAs
and stroke risk [69]. The 8 prospective studies that met the inclu-
sion criteria included 242,076 participants who reported 5238
stroke events. The overall relative risk of stroke was 0.90 (95% CI:
0.81e1.01) and did not indicate a clear association between long-
chain omega-3 PUFA intake and total stroke risk. Limitations of
this study included the presence of measurement error in the
assessment of long-chain omega-3 intake, confounding risk factors,
and publication bias.
Further studies are needed to assess omega-3 therapies in the
context of current standards of clinical care in sufﬁciently large
patient populations and at higher doses. The ongoing, prospective,
randomized, double-blind Reduction in Cardiovascular Events withEPA-Intervention Trial (REDUCE-IT; NCT01492361) will assess CV
outcomes with lipid-lowering doses of IPE in high-risk patients
with hypertriglyceridemia in addition to statin therapy [70].
2.6. Omega-3 considerations
Given the high availability of omega-3 fatty acid products to the
general public, it is important to consider the potential health
beneﬁts and risks; these have been described in a recent review of
147 publications covering various dietary sources of omega-3 fatty
acids by Tur et al. [58] and a systematic review andmeta-analysis of
omega-3 fatty acids and incident T2DM by Wu et al. [71]. Overall,
Tur et al. noted no health risks with omega-3 fatty acid products
derived from ﬁsh, algae, or plant sources with the exception of
potential risks in patients with T2DM, which was noted in 2 of the
studies reviewed. In addition, they noted that while algal omega-3
fatty acids may be a suitable source for vegetarians, ﬁshy taste and
eructations may be a concern [58]. Additional CV and lipid beneﬁts
beyond those described herein were also noted by Tur et al. These
included decreased blood pressure, heart rate, and oxidative stress
(algal sources); protection effects against non-fatal myocardial
infarction, improved insulin sensitivity in hyperlipidemic adults
and improvement in CV health (plant oil sources); and reduced
oxygen demand on the body and myocardium, reduced athero-
thrombotic risk, reduced CV disease morbidity and mortality, pre-
vention of inﬂammatory disease development, and reduced CV risk
(ﬁsh oil sources) [58]. Krill oil products may have added beneﬁts for
oxidative damage prevention given their higher levels of antioxi-
dants compared with ﬁsh and plant oil products [58]. In analyzing
16 studies, Wu et al. found there was no harmful or beneﬁcial as-
sociation of dietary EPA and DHA consumption with the develop-
ment of T2DM, but plant-derived ALA may have been associated
with a nonsigniﬁcant trend toward lower risk; substantial hetero-
geneity across ﬁndings may have been a limiting factor in the
analysis [71].
Further considerations that may have clinical bearing include
the differences between dietary supplements and prescription
omega-3 fatty acid drugs. Primary among these differences is that
manufacturers of dietary supplements are not required to
demonstrate the clinical efﬁcacy of their products [72,73]. More-
over, the content, purity and consistency of dietary supplements
are not as rigorously regulated as prescription drugs [72]. An in-
dependent analysis of 24 dietary ﬁsh oil supplements revealed that
the actual omega-3 fatty acid content ranged from <20% to >80%
more than the concentrations stated on the label; quality issues
ranged from spoilage at the time of purchase to premature release
of oil from softgel capsules [74]. In addition to uncontrolled/un-
known amounts of EPA and DHA, dietary supplements may also
contain other fats including cholesterols [10].
3. Conclusions
In the management of dyslipidemia, LDL-C remains the primary
target for lipid-lowering therapy. If LDL-C goal cannot be achieved
by therapeutic lifestyle changes or statin treatment, ﬁbrates, nia-
cins, bile acid sequestrants, cholesterol absorption inhibitors, and
marine omega-3 fatty acids may be considered to help reduce CV
risk. For patients who experience adverse events with other op-
tions, omega-3 fatty acids offer a safe and well-tolerated alterna-
tive, although dietary supplements and prescription drugs
containing both EPA and DHA have been shown to increase LDL-C
levels, potentially compromising therapy. Recent CV outcomes
studies have failed to provide clear support for the use of ﬁbrates,
niacins, cholesterol absorption inhibitors, or omega-3 EPA and DHA
combinations as adjuncts to statin therapy. The need therefore
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outcomes studies. IPE is a high-purity prescription form of EPA
ethyl ester and has been shown to lower TG levels without raising
LDL-C levels, alone or in combination with statin therapy. The
ongoing IPE REDUCE-IT study will help to address the need for
additional CV outcomes data with 4 g/day of an EPA-only omega-3
fatty acid therapy in statin-treated patients with hyper-
triglyceridemia and established CV disease or at high risk for CV
disease.
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